CN110585379A - External application medicine for treating dermatitis - Google Patents
External application medicine for treating dermatitis Download PDFInfo
- Publication number
- CN110585379A CN110585379A CN201810604186.XA CN201810604186A CN110585379A CN 110585379 A CN110585379 A CN 110585379A CN 201810604186 A CN201810604186 A CN 201810604186A CN 110585379 A CN110585379 A CN 110585379A
- Authority
- CN
- China
- Prior art keywords
- parts
- dermatitis
- normal temperature
- raw material
- external application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 67
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 239000002994 raw material Substances 0.000 claims abstract description 39
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 13
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 13
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 12
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 12
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 12
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 12
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 12
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 12
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 12
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 12
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 12
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 241001092040 Crataegus Species 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000004537 pulping Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 208000010668 atopic eczema Diseases 0.000 abstract description 14
- 206010067197 Tinea manuum Diseases 0.000 abstract description 12
- 201000004647 tinea pedis Diseases 0.000 abstract description 10
- 230000000857 drug effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 208000003251 Pruritus Diseases 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000007803 itching Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010063409 Acarodermatitis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000447727 Scabies Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000007721 medicinal effect Effects 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000005687 scabies Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 235000018274 Cunila origanoides Nutrition 0.000 description 4
- 235000014866 Dictamnus albus Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 240000000774 Cunila origanoides Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 208000008350 Pruritus Vulvae Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001252601 Blumea Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000517307 Pediculus humanus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- 241001671204 Stemona Species 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000182625 Dictamnus albus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018999 Haemorrhage subcutaneous Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021746 Infantile colic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003789 metatarsus Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external application medicine for treating dermatitis, which comprises the following raw material medicines in parts by weight: 20-40 parts of folium artemisiae argyi, 5-20 parts of safflower, 20-40 parts of radix sophorae flavescentis, 10-30 parts of cortex dictamni, 10-30 parts of radix stemonae and 10-30 parts of raw hawthorn; in the preparation process, the raw material medicines are processed under the normal temperature condition, wherein the normal temperature condition is a temperature value which does not exceed the limit temperature range value of destroying the active ingredients of the traditional Chinese medicine raw materials. The external application medicine for treating dermatitis, provided by the invention, has the advantages of obvious drug effect and small side effect in treating dermatitis, such as eczema, tinea pedis, tinea manuum and the like.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to an external application medicine for treating dermatitis.
Background
In the broadest sense, dermatitis is inflammatory dermatitis of the skin, and is commonly referred to as contact dermatitis, atopic dermatitis, stasis dermatitis, seborrheic dermatitis, and the like. This is a common aesthetic skin condition that requires timely and effective treatment. However, dermatitis symptoms vary from disease cause to disease cause. Although different types of dermatitis have different symptoms, they all have some common signs, including redness, swelling, itching, skin damage, and sometimes weeping and scarring.
At present, the dermatitis is treated by western medicine treatment, instrument treatment and traditional Chinese medicine treatment.
The western medicine for treating dermatitis mostly adopts oral antihistamine medicines and temporary corticoid medicines, such as oral western medicines, oral hormones, external solution lotion, emulsion, paste, oil, ointment, emulsion, plastics, tincture, hard paste and the like. The long-term or large-dose external use of corticoid drugs can lead to drug dependence due to addiction, the disease condition is improved after the drug is taken most commonly, and the primary lesion of the applied part is aggravated once the drug is stopped. After the hormone is reused, the disease condition is improved or disappeared; if the medicine is stopped again, the rebound recurs and is more serious than before. It can also cause obesity, hirsutism, acne, blood sugar increase, hypertension, edema, blood potassium decrease, menstrual disorder, osteoporosis, aseptic osteonecrosis, and gastric and duodenal ulcer. Can also cause certain damage to the kidney, such as aggravating glomerular disease proteinuria, aggravating glomerular sclerosis, easily causing renal calcification or calculus, inducing or aggravating kidney infectious diseases, causing low-potassium nephropathy, and the like. It also causes metabolism disorder of sugar, protein, fat and water electrolyte, destroys defense system and inhibits immune reaction.
And (3) instrument treatment: the skin allergy is forcibly removed by violating the natural law of skin metabolism. The skin is easy to be stained and easy to recur due to the possibility of damage to the stratum corneum and even atrophy of the stratum corneum. Traditional Chinese medicine treatment: the traditional Chinese medicine is three-way toxic, the efficacy of the traditional Chinese medicine has diversity, effective active ingredients cannot be accurately defined, the modern biological engineering technology is lacked, and partial traditional Chinese medicine ingredients can cause allergy. Cosmetic for external use: the skin allergy symptom can be improved only from the surface layer of the skin, the pertinence is single, and the treatment is temporary and permanent. Some topical products may contain irritating ingredients, hormones, harmful chemicals that directly contact the damaged skin. It can quickly relieve symptoms in a short time, but the medicine has large side effect and generates dependence, the symptoms can be repeatedly attacked, and the skin is more sensitive. Patients are completely hormone dependent to avoid pain after withdrawal. The skin becomes thin obviously, the blood capillary expands, purpura sometimes appears, and the like, and particularly deeper and continuous erythema can appear on the face. The longer the hormone is used, the more severe the rebound hypersensitivity develops. Can be used for treating skin thinning, skin fragility, skin atrophy, telangiectasia, purpura, fungal infection, and acne-like dermatitis. Become vulnerable to damage; mild hirsutism, hyperhidrosis, subcutaneous bleeding, and difficulty in wound healing may also occur. Especially, some skin diseases are not suitable for hormone preparations.
The dermatitis is mainly treated by oral decoction in the traditional Chinese medicine, so that the problems of drug property loss, bitter taste and the like in the high-temperature decoction process exist, the treatment is inconvenient, and certain side effects also exist when the dermatitis is orally taken.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: provides an external application medicament for treating dermatitis, which has remarkable drug effect and small side effect in treating dermatitis such as eczema, tinea pedis, tinea manuum and the like.
In order to solve the technical problems, the technical scheme of the invention is as follows:
an external application medicine for treating dermatitis comprises the following raw material medicines in parts by weight: 20-40 parts of folium artemisiae argyi, 5-20 parts of safflower, 20-40 parts of radix sophorae flavescentis, 10-30 parts of cortex dictamni, 10-30 parts of radix stemonae and 10-30 parts of raw hawthorn;
in the preparation process, the raw material medicines are processed under the normal temperature condition, wherein the normal temperature condition is a temperature value which does not exceed the limit temperature range value of destroying the active ingredients of the traditional Chinese medicine raw materials.
Preferably, the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 26 parts of folium artemisiae argyi, 9 parts of safflower, 26 parts of radix sophorae flavescentis, 13 parts of cortex dictamni, 13 parts of radix stemonae and 13 parts of raw hawthorn.
Preferably, the raw material medicines are superfine ground into powder at normal temperature.
Preferably, the raw material medicines are prepared into paste at normal temperature.
Preferably, the raw material medicines are prepared into a water agent at normal temperature.
Preferably, the fresh raw material medicines are ground, pulped or squeezed into juice at normal temperature.
After the technical scheme is adopted, the invention has the beneficial effects that:
the invention relates to an external application medicine for treating dermatitis, which is a traditional Chinese medicine composition. In vitro experiments prove that the blumea oil has an inhibiting effect on cocci and most gram-negative bacilli. Animal experimental studies show that: the blumea oil can increase the phagocytic ability of inflammatory exudative cells of mice after gastric administration. The cortex dictamni radicis has the effects of clearing heat, eliminating dampness, dispelling wind, relieving itching and detoxifying, and the modern pharmacological research shows that: in vitro test 1:4 the cortex Dictamni water extract has different degrees of inhibition on various pathogenic fungi such as Trichophyton violaceum, Trichophyton concentricum and Trichophyton schoenleinii. Stemona root, radix Stemonae has the effects of warming and moistening lung qi, relieving cough, and killing parasites. In addition, it also has good therapeutic effect on scabies and eczema. Modern researches have proved that radix Stemonae contains various alkaloids, and has inhibitory effect on various cocci, bacilli and dermatophytes. The hawthorn can promote digestion and remove food retention and dispel blood stasis, and pharmacological studies show that: the flavonoids, vitamin c, carotene, etc. contained in fructus crataegi can block and reduce the generation of free radicals, enhance immunity, and inhibit bacteria. Animal experiments show that: the injection prepared by decocting fructus crataegi with water and precipitating with ethanol can be administered for 9 days, so as to significantly enhance rabbit serum lysozyme activity, blood serum hemagglutination antibody titer, heart blood T lymphocyte E rosette formation rate and T lymphocyte conversion rate, and indicate immune enhancement effect. Radix Sophorae Flavescentis has effects of clearing heat and toxic materials, eliminating dampness and promoting diuresis, dispelling pathogenic wind and killing parasites, and ancient and modern prescriptions are used for treating wind-heat sores and rashes. Modern researches show that the sophora flavescens has the characteristics of disinfection and sterilization, disinfection on bacterial propagules, viruses and fungi (mold), no stimulation to skin and low sensitization. The safflower has the effects of activating blood and stimulating the menstrual flow, removing blood stasis and relieving pain and the like, and various active ingredients in the safflower can influence immunity, antagonize PAF receptors, improve the level of NO in vivo, clear oxygen free radicals, antagonize various inflammatory factors and have effective and good anti-inflammatory action. The main active ingredient Safflower Yellow (SY) can reduce the content of serum lysozyme, inhibit the delayed hypersensitivity reaction and the generation of serum hemolysin, inhibit the phagocytic function of abdominal cavity macrophages and whole blood leukocytes and reduce the formation cells of spleen-specific rose. The application of SY in vitro can inhibit proliferation reaction of T/B lymphocyte doped with 3H, TdR, mixed lymphocyte reaction, interleukin-2 level and activity, and T cell generation and activity. In addition, SY has obvious inhibition effect on the swelling of feet of formaldehyde rats, the increase of the permeation quantity of capillary vessels of the skin of the rats caused by histamine and the formation of cotton ball granuloma of the rats, and the anti-inflammatory mechanism is probably to reduce the permeability of the capillary vessels, reduce inflammatory exudation, inhibit the inflammatory process and granuloma hyperplasia. The components have the synergistic effect, and the composition has the effects of eliminating dampness and relieving itching, promoting qi and blood circulation to dissipate blood stasis, eliminating dampness, clearing heat, detoxifying, sterilizing, diminishing inflammation, blocking and reducing the generation of free radicals, enhancing the immunity of the organism and inhibiting bacteria, is externally applied to dermatitis such as eczema, tinea pedis, tinea manuum and the like of a patient, does not need to be orally taken, and is convenient for the patient to use. Has excellent curative effect on dermatitis such as eczema, tinea pedis, tinea manuum and the like, high cure rate and high safety factor, and is popular with patients.
In addition, in the process of preparing the externally applied dermatitis treatment medicament, the raw material medicaments are processed under the normal temperature condition, wherein the normal temperature condition is a temperature value which does not exceed the limit temperature range value of destroying the active ingredients of the traditional Chinese medicine raw materials. The high-temperature processing means such as steaming, boiling, burning and the like are not needed, the active ingredients and active groups in the raw material medicines are not damaged, the full medicinal property of the raw material medicines can be reserved, the use effect of the dermatitis treatment medicine is greatly improved, the traditional processing method of the traditional Chinese medicine is overturned, and the use efficiency of the traditional Chinese medicine is improved.
Detailed Description
The basic conditions of the nature, the flavor, the meridian tropism, the function and the application of the main raw materials are introduced according to Chinese pharmacopoeia, Chinese dictionary and Chinese herbal medicine.
Folium artemisiae argyi: pungent, bitter and warm. It enters liver, spleen and kidney meridians. Warming channels to stop bleeding, dispelling cold and relieving pain; externally used for eliminating dampness and relieving itching. Can be used for treating hematemesis, epistaxis, metrorrhagia, menorrhagia, fetal leakage, lower blood, lower abdomen psychroalgia, menoxenia, and infertility due to cold womb; it can be used for treating skin pruritus. Vinegar moxa charcoal can warm meridians and stop bleeding, and is indicated for bleeding due to deficiency-cold.
Safflower: pungent and warm. Enter heart and liver meridians. The function is mainly used; promoting blood circulation, dredging channels, removing blood stasis and relieving pain. It is indicated for amenorrhea, abdominal mass, dystocia, dead fetus, postpartum lochiorrhea, pain due to blood stasis, carbuncle, swelling and traumatic injury.
Flavescent sophora root: is bitter in taste; is cold in nature. Liver diseases entering; a kidney; the large intestine; the small intestine channel; the bladder; the heart meridian; the bladder channel. Clearing heat and eliminating dampness; dispel wind and kill parasites. Diarrhea and dysentery due to damp-heat; hematochezia due to intestinal wind; jaundice; difficulty in urination; edema; leucorrhea; pruritus vulvae; scabies; leprosy; itch of the skin; sores and ulcers due to damp-toxicity. Treating leukorrhagia and pruritus vulvae; eczema and scabies. The sophora flavescens bath can clear damp-heat in lower jiao, kill parasites and relieve itching, and has good relieving effect on skin pruritus caused by eczema and scabies.
Dittany bark, cortex Dictamni Radicis, bitter and salty taste, cold. Enter spleen and stomach meridians. Dispel wind, dry dampness, clear heat and remove toxicity. It is used to treat sore due to wind-heat, scabies, tinea, prurigo, rheumatic arthralgia, and jaundice.
Stemona root: slightly warm in nature, sweet and bitter in taste. It enters lung meridian. Killing insects and lice. Can be used for treating cough due to chronic illness, cough due to lung strain, and cough due to lung-blowing; it is externally used for treating head louse, body louse, enterobiasis, and pruritus vulvae.
Raw hawthorn: sour and sweet, slightly warm. Enter spleen, stomach and liver meridians. Promoting digestion, removing blood stasis, expelling tapeworm. It is used for treating meat stagnation, abdominal mass, phlegm retention, abdominal distention, acid regurgitation, dysentery, intestinal wind, lumbago, infantile colic, abdominal pain, lochiorrhea, and infantile dyspepsia. Promote digestion, invigorate stomach, promote qi circulation and dissipate blood stasis. Can be used for treating dyspepsia, flatulence, dysentery, abdominal pain, blood stasis, amenorrhea, puerperal stagnation, heart and abdominal pain, hernia pain, and hyperlipidemia. Pharmacological studies have shown that: the flavonoids, vitamin c, carotene, etc. contained in fructus crataegi can block and reduce the generation of free radicals, enhance immunity, and inhibit bacteria. Animal experiments show that: the injection prepared by decocting fructus crataegi with water and precipitating with ethanol can be administered for 9 days, so as to significantly enhance rabbit serum lysozyme activity, blood serum hemagglutination antibody titer, heart blood T lymphocyte E rosette formation rate and T lymphocyte conversion rate, and indicate immune enhancement effect. Radix Sophorae Flavescentis has effects of clearing heat and toxic materials, eliminating dampness and promoting diuresis, dispelling pathogenic wind and killing parasites, and ancient and modern prescriptions are used for treating wind-heat sores and rashes.
The following description is given of specific embodiments of the present invention, which are provided for illustration only and are not intended to limit the scope of the present invention.
Example one
The externally applied medicine for treating dermatitis comprises the following raw material medicines in parts by weight: 30g of folium artemisiae argyi, 10g of safflower, 30g of radix sophorae flavescentis, 15g of cortex dictamni, 15g of radix stemonae and 15g of raw hawthorn.
The raw materials are soaked in water at normal temperature and then are crushed into aqua which is used as an external application medicine for treating dermatitis.
Or micronizing the raw materials into powder at normal temperature, and making into topical medicine for treating dermatitis. The ultrafine powder has a particle size of 50-650 meshes, and can be easily absorbed by body absorption parts such as skin of a patient.
The normal temperature condition is a temperature value which does not exceed the limit temperature range value of active ingredients of the raw material medicines, and generally means not to exceed 62 ℃.
Example two
The externally applied medicine for treating dermatitis comprises the following raw material medicines in parts by weight: 20g of folium artemisiae argyi, 5g of safflower, 40g of radix sophorae flavescentis, 10g of dittany bark, 20g of radix stemonae and 20g of raw hawthorn.
In the preparation process of the externally applied medicine for treating dermatitis, the raw material medicines are superfine crushed into powder at normal temperature to be used as the externally applied medicine for treating dermatitis. The ultrafine powder has a particle size of 50-650 meshes, and can be easily absorbed by body absorption parts such as skin of a patient.
The normal temperature condition is a temperature value which does not exceed a limit temperature range value of destroying active ingredients of the raw material medicines, and generally means not exceeding 62 ℃.
EXAMPLE III
The externally applied medicine for treating dermatitis comprises the following raw material medicines in parts by weight: 40g of folium artemisiae argyi, 20g of safflower, 20g of radix sophorae flavescentis, 15g of dittany bark, 15g of radix stemonae and 10g of raw hawthorn.
The raw material medicines are subjected to superfine grinding at normal temperature, the superfine grinding particle size is in a particle size range of 50-650 meshes, and the raw material medicines are easily absorbed by body absorption parts such as skin of a patient. Then vaseline and honey are added to prepare ointment which is used as an external application medicine for treating dermatitis. The normal temperature condition is a temperature value which does not exceed the limit temperature range value of active ingredients of the raw material medicines, and generally means not to exceed 62 ℃.
Example four
The externally applied medicine for treating dermatitis comprises the following raw material medicines in parts by weight: 10g of folium artemisiae argyi, 15g of safflower, 30g of radix sophorae flavescentis, 20g of dittany bark, 15g of radix stemonae and 30g of raw hawthorn.
The folium artemisiae argyi, the safflower, the radix sophorae flavescentis, the cortex dictamni, the radix stemonae and the raw hawthorn in the components can be prepared by adopting fresh raw materials, mixing, grinding, pulping or juicing at normal temperature, or respectively pulping and mixing the single fresh raw materials. Can be used as external medicine for treating dermatitis. The normal temperature condition is a temperature value which does not exceed a limit temperature range value of destroying active ingredients of the raw material medicines, and generally means not exceeding 62 ℃.
Clinical data
1. Basic data: the inventors collected 48 patients in total, including cases of eczema and tinea pedis, tinea manuum, and eczema test group: test group 1 to test group 4, 6 cases each; tinea pedis, tinea manuum test group: test groups 5 to 8, 6 cases each.
(1) Eczema test group
Test group 1, 6 cases in this group, age 17-64 years, mean age 34.7 years.
Test group 2, 6 examples of this group, aged 18-63 years, with an average age of 35.1 years.
Test group 3 in 6 cases of this group, age 19-64 years, mean age 35.4 years.
Test group 4, 6 cases of this group, aged 16-65 years, with the average age of 34.9 years.
(2) Tinea pedis and tinea manuum test group
Test group 5 in 6 cases of this group, age 17-64 years, mean age 34.4 years.
Test group 6 in the 6 cases of this group, the age was 16-63 years, and the average age was 33.8 years.
Test group 7 in 6 cases of this group, age 19-65 years, mean age 35.3 years.
Test group 8, 6 cases in this group, aged 18-62 years, the average age was 35.4 years.
2. Diagnostic criteria:
(1) eczema is mainly based on the history, form and course of rash. Generally, eczema is characterized by multiple skin lesions, mainly erythema, pimple and herpes simplex, with the central rash gradually spreading to the periphery, unclear boundaries, diffuse nature and exudation tendency, and chronic eczema with profuse infiltration. The disease course is irregular, and the itching is severe with repeated attacks. (2) Tinea pedis and tinea manuum have blister, desquamation or white, wet and soft skin between toes, and also have erosion, skin thickening, roughness and cracking, and can spread to the metatarsus and edge of foot, causing severe itching. It can be associated with local suppuration, red swelling, pain, enlargement of inguinal lymph node, and even formation of leg erysipelas and cellulitis. Tinea manuum (tinea manuum) is often caused by the itching of the hands. When fungus grows on the nail, it causes onychomycosis (onychomycosis).
3. Treatment method and course of treatment
(1) Eczema test group
Test group 1A topical medicine for treating dermatitis (example 1) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
Test group 2. the externally applied medicine for treating dermatitis (example 2) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
Test group 3. the externally applied medicine for treating dermatitis (example 3) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
Test group 4. the externally applied medicine for treating dermatitis (example 4) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
(2) Tinea pedis and tinea manuum test group
Test group 5 the externally applied medicine for treating dermatitis (example 1) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
Test group 6, the external application medicine for treating dermatitis (example 2) is applied to the affected part once every four hours, and 7 days are one treatment course and one treatment course is applied.
Test group 7. the externally applied medicine for treating dermatitis (example 3) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
Test group 8, the external application medicine for treating dermatitis (example 4) of the invention is applied to the affected part once every four hours, and is applied for 7 days as a treatment course and a treatment course.
4. Standard of therapeutic effect
And (3) healing: clinical symptoms all disappeared;
the method has the following advantages: the clinical symptoms are reduced;
and (4) invalidation: no obvious improvement or aggravation of clinical symptoms;
5. the curative effect is as follows:
test group 1: the patients are cured for 7, 1 effective and 1 ineffective.
Test group 2: and 8 patients are cured.
Test group 3: 6 patients are cured, and 2 patients are effective.
Test group 4: the patients were cured for 7 and the patients were not cured for 1.
Test group 5: and 8 patients are cured.
Test group 6: the patients are cured for 7 people, and the effective rate is 1 person.
Test group 7: the patients are cured for 7 people, and the effective rate is 1 person.
Test group 8: and 8 patients are cured.
After the traditional Chinese medicine is externally applied, 41 cases are cured, 5 cases are effective, 2 cases are ineffective, and the total effective rate is 95.8%.
The dermatitis treating medicine is a percutaneous absorption method, various plant and animal medicines which need to be processed at normal temperature are used in a raw or fresh mode, so that pathogens which cause body diseases are treated from two aspects of bioactive factors and physicochemical medicinal property factors, the percutaneous absorption generally does not absorb substances of various medicines, but only absorbs the bioactivity or medicinal property of the medicines, the harm to the body is reduced, and the local absorption and the local treatment of specific parts of the body or the whole body smearing treatment can be realized.
The dermatitis treating medicine is a percutaneous absorption method, various plant and animal medicines which need to be processed at normal temperature are used in a raw or fresh mode, so that pathogens which cause body diseases are treated from two aspects of bioactive factors and physicochemical medicinal property factors, the percutaneous absorption generally does not absorb substances of various medicines, but only absorbs the bioactivity or medicinal property of the medicines, the harm to the body is reduced, and the local absorption and the local treatment of specific parts of the body or the whole body smearing treatment can be realized.
At present, western medicines are abused, the application and popularization of the traditional Chinese medicines are extremely slow, the inventor of the application focuses on traditional Chinese medicine research for years, and finds out the prescription of the application in long-term theoretical research and multi-case clinical tests, and the prescription has obvious drug effect and small side effect when used for treating dermatitis such as eczema, tinea pedis, tinea manuum and the like. And each component in the prescription is lack of one, the curative effect is greatly reduced, so the prescription is determined, and the contribution to the development of the traditional Chinese medicine is hopefully made.
The foregoing is illustrative of the best mode of the invention and details not described herein are within the common general knowledge of a person of ordinary skill in the art. The scope of the present invention is defined by the appended claims, and any equivalent modifications based on the technical teaching of the present invention are also within the scope of the present invention.
Claims (6)
1. The externally applied medicine for treating the dermatitis is characterized by comprising the following raw material medicines in parts by weight: 20-40 parts of folium artemisiae argyi, 5-20 parts of safflower, 20-40 parts of radix sophorae flavescentis, 10-30 parts of cortex dictamni, 10-30 parts of radix stemonae and 10-30 parts of raw hawthorn;
in the preparation process, the raw material medicines are processed under the normal temperature condition, wherein the normal temperature condition is a temperature value which does not exceed the limit temperature range value of destroying the active ingredients of the traditional Chinese medicine raw materials.
2. The externally applied medicine for treating dermatitis as claimed in claim 1, which comprises the following raw material medicines in parts by weight: 26 parts of folium artemisiae argyi, 9 parts of safflower, 26 parts of radix sophorae flavescentis, 13 parts of cortex dictamni, 13 parts of radix stemonae and 13 parts of raw hawthorn.
3. A medicament for external application in the treatment of dermatitis as claimed in claim 1 or 2, wherein: the raw material medicines are superfine crushed into powder at normal temperature.
4. A medicament for external application in the treatment of dermatitis as claimed in claim 1 or 2, wherein: the raw materials are prepared into paste at normal temperature.
5. A medicament for external application in the treatment of dermatitis as claimed in claim 1 or 2, wherein: the raw material medicines are prepared into a water agent at normal temperature.
6. A medicament for external application in the treatment of dermatitis as claimed in claim 1 or 2, wherein: grinding and pulping or juicing the fresh raw materials at normal temperature.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810604186.XA CN110585379A (en) | 2018-06-13 | 2018-06-13 | External application medicine for treating dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810604186.XA CN110585379A (en) | 2018-06-13 | 2018-06-13 | External application medicine for treating dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110585379A true CN110585379A (en) | 2019-12-20 |
Family
ID=68848853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810604186.XA Pending CN110585379A (en) | 2018-06-13 | 2018-06-13 | External application medicine for treating dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110585379A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114288366A (en) * | 2021-12-14 | 2022-04-08 | 广西医科大学第一附属医院 | A kind of medicinal bath composition and its preparation method and application |
-
2018
- 2018-06-13 CN CN201810604186.XA patent/CN110585379A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114288366A (en) * | 2021-12-14 | 2022-04-08 | 广西医科大学第一附属医院 | A kind of medicinal bath composition and its preparation method and application |
| CN114288366B (en) * | 2021-12-14 | 2023-03-10 | 广西医科大学第一附属医院 | A medicinal bath composition for preventing and treating skin diseases of bedridden patients and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103070961A (en) | Chinese medicinal anti-bacteria health care foot-massage solution and preparation method thereof | |
| KR20100079858A (en) | The new medicine for skin disease composed of mineral and medical herbs | |
| CN100387291C (en) | Medicine for treating pulmonary tuberculosis | |
| CN106421392A (en) | Traditional Chinese medicinal gel for treating bedsore and preparation method of traditional Chinese medicinal gel | |
| CN103638316B (en) | Traditional Chinese medicine preparation for treating dermatitis | |
| CN102688434B (en) | A kind of traditional Chinese medicine for treating diabetes | |
| CN105535822A (en) | Traditional Chinese medicine composition for treating haemorrhoids and preparation method thereof | |
| CN110585379A (en) | External application medicine for treating dermatitis | |
| CN116370576A (en) | Traditional Chinese medicine granulation-promoting ointment for repairing wounds and preparation method thereof | |
| CN104524174A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method thereof | |
| CN104784637B (en) | A kind of Chinese medicine composition of lavipeditum treatment diabete peripheral herve pathology | |
| CN107648444A (en) | A kind of slow release cutaneous penetration for vulva seborrhea pastes | |
| CN102228652A (en) | Chinese medicinal composition for treating chronic peritonitis and preparation method thereof | |
| CN103041194B (en) | Traditional Chinese medicine composition for curing chronic eczema and preparation method thereof | |
| CN105031595A (en) | Traditional Chinese medicine tablet for treating nummular eczema and preparing method thereof | |
| CN105327244A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and used for treating bedsores and preparing method thereof | |
| CN104189489A (en) | Medicament with effect of treating chronic eczema and preparation method thereof | |
| CN104042923A (en) | Externally-applied cream for treating whelk | |
| CN112294894B (en) | A kind of pure traditional Chinese medicine preparation for treating hemorrhoids | |
| CN103223151A (en) | Traditional Chinese medicinal composition for brightening and spot-removing and preparation method of preparation | |
| CN105343423A (en) | Eczema treatment medicine and preparation method thereof | |
| CN104666784A (en) | Acne treating capsules and preparation method thereof | |
| CN105770115A (en) | Traditional Chinese medicine ointment for treating eczema | |
| CN104784541B (en) | It is a kind of to be used to remove Chinese drugs agentia of acne and preparation method thereof | |
| CN119113075A (en) | A kind of patch for treating oral ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191220 |